Knowledge HQ

Production of a third-party CMV-specific T cell (CMVST) bank. Cells were expanded using G-Rex 5 and G-Rex 100M. The bank successfully provided matched lines for 96.6% of screened patients with 100% response rate in treated patients.

Development of 'NKF' feeder cells (OCI-AML3 with mbIL-21) for NK expansion. The system allows large-scale expansion (>10,000 fold) and was validated in G-Rex. Expanded NK cells showed high cytotoxicity and metabolic activation.

Case report of a pediatric patient with relapsed Ewing sarcoma treated with intratumoral injections of NK-92 cells. NK-92 cells were expanded in GMP conditions using the G-Rex culture system. Local tumor regression was observed.

Clinical trial of mRNA-engineered NKG2D CAR-NK cells in metastatic colorectal cancer. NK cells were expanded from PBMCs using K562 feeder cells in G-Rex 100 vessels. Treatment was safe and showed tumor regression in local injection sites.

Study on extracellular vesicles (EVs) derived from NK cells. NK cells were propagated and activated using K562-mbIL21 aAPCs in G-Rex culture devices. NK-EVs contained cytotoxic proteins and induced cell death in cancer cells via multiple mechanisms.

Demonstrated multiplex base editing (PDCD1, TRAC, B2M) in T cells to create allogeneic CAR-T cells. Edited cells were expanded in G-Rex vessels. The method reduced double-strand breaks and translocations compared to Cas9 nuclease.

Study on gene editing T cells to place CAR and IL-12P70 under endogenous control (TRAC, IL2Ra, PDCD1). TRACCAR T cells were expanded in G-Rex 10 devices. The engineered cells showed regulated cytokine secretion and improved anti-tumor activity.

Patent describing the Gen 2 manufacturing process for TILs. Detailed methods include the use of G-Rex 100M and G-Rex 500M for the Rapid Expansion Protocol (REP) to shorten culture time and improve efficiency compared to the Gen 1 process.

Clinical data on Lifileucel (LN-144) for metastatic melanoma. The manufacturing process involves a 22-day protocol using G-Rex. Shows 40.5% ORR in primary refractory patients.

Poster describing the Iovance Gen 2 TIL manufacturing process which utilizes G-Rex for the Rapid Expansion Protocol (REP). Data shows success across melanoma, cervical, HNSCC, sarcoma, and lung cancers with high viability and T-cell purity.

This study develops a protocol for expanding polyclonal γδ memory T cells using artificial antigen-presenting cells in G-Rex. The method yields large numbers of potent, non-alloreactive T cells with broad anti-tumor activity. This platform supports the creation of off-the-shelf immunotherapies.

Mycobacteria-specific T cells (MSTs) were expanded from healthy donors using peptide pools and G-Rex 10. The protocol yielded polyfunctional CD4+ T cells. MSTs were largely absent in patients with primary immunodeficiencies.